1. Market Research
  2. > Pharmaceutical Market Trends
Non-Animal Alternatives Testing Global Market Report 2022

Non-Animal Alternatives Testing Global Market Report 2022

  • December 2021
  • 400 pages
  • ID: 6193737
  • Format: PDF
  • The Business Research Company


Table of Contents

Major players in the non-animal alternatives testing are MatTek Corporation, Cyprotex, Emulate Inc, BioIVT, Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories and Gentronix Limited.

The global non-animal alternatives testing market is expected to grow from $1.63 billion in 2021 to $1.78 billion in 2022 at a compound annual growth rate (CAGR) of 9.08%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.59 billion in 2026 at a CAGR of 9.83%.

The non-animal alternatives testing market consists of sales of non-animal alternatives testing products and services that do not involve testing on animals to determine the safety and efficacy of products and ingredients used in any industry sector.Non-animal alternative testing technologies include: in-vitro human cell and tissue cultures, organs-on-chips (OOCs), computer simulations and modelling (silico models), 3D bio-printing of tissues, and synthetic skin substitutes as well as studies with human volunteers.

These technologies replace animal testing in end-use industries including pharmaceuticals, medical devices, chemicals & pesticides, food, and others.

The main methods of non-animal alternative testing are cellular assay, biochemical assay, in silico, and ex-vivo.A biochemical assay is an in vitro analytical process used to detect, quantify, and/or investigate the binding or activity of a biological molecule, such as an enzyme.

The various technologies used include cell culture technology, high throughput technology, molecular imaging, omics technology, and other technologies. These are utilized by industries such as pharmaceutical industry, cosmetics & household products, diagnostics, chemicals industry, and food industry.

North America was the largest region in the non-animal alternatives testing in 2021.Western Europe was the second-largest region in the non-animal alternatives testing market.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The support from the government and non-governmental organisations boosts the growth of the non-animal testing market.The government organisations enforces laws and regulations, raises funds to support the non-animal testing methods such as tests on human volunteers, advanced computer-modelling techniques and also funds studies with human volunteer.

In order to support the non-animal testing, US Environmental Protection Agency (EPA), in 2019, awarded $4.25 million to the USA based universities including Johns Hopkins University, Vanderbilt University, Oregon State University, and the University of California to research for alternative tests replacing animals with non-animal alternatives and to make the test procedures less painful to the laboratory animals. Similar research programs to promote non-animal testing procedures are also initiated by countries such as Denmark, Brazil, Germany, Switzerland, Australia, China and Korea. The constant support from the government drives the growth of the non-animal testing market.

OOCs (organs-on-chips) tool for testing is a major trend in the non-animal alternatives testing market.Organs-on-a-chips (OOCs) are miniature tissues and organs grown in-vitro that enable the modeling of human physiology and disease.

OOCs are now being explored worldwide as tools for developing disease models and accurately predicting drug efficacies and toxicities.The advantages of OOCs over cell culture, animal models, and human clinical trials have captured the attention of both the medical and pharmaceutical communities focusing on developing targeted therapies.

For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) in the US, developed a new model for Organs-on-a-Chip to develop treatments for inflammatory diseases and afflictions. Organs-on-a-chip consists of millions of cells formed on a platform to replicate the functions of different organs and can be used as an instrument in analyzing and creating new treatments for complex diseases without the use of animals for testing.

Stringent regulations related to safety, efficacy, and quality are projected to act as a major challenge for players operating in the non-animal alternatives testing market.All medicines and treatments go through stringent testing in the lab (pre-clinical research) and in small groups of patients (clinical research).

The European Medicines Agency (EMA) and The US (FDA) are the two main bodies regulating these novel therapies while getting them to market.Health Canada uses mAb specific guidelines from EMA or USFDA when necessary.

The SAHPRA (South African Health Products Authority) biosimilar guideline has an annex on mAbs which focuses on non-clinical and clinical aspects.The Russian Federation has issued general product registration guideline/s with very brief information about mAbs.

Since it is a time-consuming process, it is considered as one of the major hindering factors for the non-animal alternatives testing market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

L-carnitine Market Research Report by Product, Process, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • July 2022
  • 242 pages

L-carnitine Market Research Report by Product (Feed Grade, Food Grade, and Pharmaceutical Grade), Process, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast ...

  • World
  • Pharmaceutical
  • Marketing Research
  • Industry analysis


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on